Alector Inc. (0Z2)

Overview

Alector, Inc. is a pioneering clinical-stage biopharmaceutical company, dedicated to breaking new ground in the treatment of neurodegeneration diseases. Since its establishment in 2013, Alector has focused on developing innovative therapies that target key aspects of neurodegenerative disorders. The company is engaged in rigorous research and development efforts, leveraging its expertise in biotechnology to create solutions that could potentially transform the treatment landscape for conditions such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, among others. Headquartered in South San Francisco, California, Alector is propelled by strategic collaborations with entities like Adimab, LLC, for antibody research and development, and GlaxoSmithKline plc, focusing on the development and commercialization of specific monoclonal antibodies targeting neurodegenerative diseases.

Products and Services

• AL001 - This promising drug candidate is in Phase III clinical trials and targets immune activity within the brain that has genetic connections to a variety of neurodegenerative disorders. AL001 has the potential to treat frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis by leveraging the immune system's role in these diseases.
• AL101 - Currently in Phase I clinical trials, AL101 represents Alector's commitment to expanding its portfolio of treatments across the spectrum of neurodegenerative diseases. Focusing primarily on Alzheimer's and Parkinson's diseases, AL101 is evaluated for its potential to modify the course of these challenging conditions.
• AL002 - This product candidate is in the midst of Phase II clinical trials, aimed specifically at treating Alzheimer's disease. By focusing on unique targets within the Alzheimer's disease pathology, AL002 stands as a testament to Alector's innovative approach to tackling this prevalent and debilitating condition.